News | March 06, 2025
Zydus Lifesciences launches ANVIMO
ANVIMO will be available in dosages of 240 mg and 480 mg
ANVIMO will be available in dosages of 240 mg and 480 mg
In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025
The PIPE offering consists of 36,190,476 units
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Offers affordable, high-quality solutions for diabetes care
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Branded formulation business continues to perform well across domestic and export markets
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Subscribe To Our Newsletter & Stay Updated
